Cambridge Investment Research Advisors Inc. decreased its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 450,791 shares of the company's stock after selling 13,408 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in Merck & Co., Inc. were worth $44,845,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of the stock. Capital Advantage Inc. acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $948,000. BOKF NA increased its position in shares of Merck & Co., Inc. by 13.8% in the 4th quarter. BOKF NA now owns 342,550 shares of the company's stock valued at $33,998,000 after purchasing an additional 41,452 shares during the last quarter. Bosun Asset Management LLC raised its holdings in shares of Merck & Co., Inc. by 14.0% in the 4th quarter. Bosun Asset Management LLC now owns 2,200 shares of the company's stock valued at $219,000 after purchasing an additional 271 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Merck & Co., Inc. by 15.9% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,112 shares of the company's stock worth $21,399,000 after purchasing an additional 29,549 shares during the last quarter. Finally, Brooks Moore & Associates Inc. grew its stake in shares of Merck & Co., Inc. by 0.5% during the fourth quarter. Brooks Moore & Associates Inc. now owns 47,756 shares of the company's stock worth $4,751,000 after purchasing an additional 220 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.
Insider Buying and Selling at Merck & Co., Inc.
In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the firm's stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the sale, the senior vice president now owns 7,778 shares of the company's stock, valued at approximately $643,707.28. This trade represents a 35.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Cristal N. Downing sold 2,361 shares of the company's stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $88.76, for a total transaction of $209,562.36. Following the transaction, the insider now directly owns 7,085 shares in the company, valued at approximately $628,864.60. This trade represents a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.
Merck & Co., Inc. Price Performance
Merck & Co., Inc. stock opened at $79.11 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The business has a 50 day simple moving average of $86.17 and a 200-day simple moving average of $93.82. Merck & Co., Inc. has a 12 month low of $75.93 and a 12 month high of $134.63. The stock has a market capitalization of $199.49 billion, a PE ratio of 11.75, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $2.22 EPS for the quarter, topping analysts' consensus estimates of $2.16 by $0.06. The company had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. Merck & Co., Inc.'s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.07 EPS. Equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.
Merck & Co., Inc. declared that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 4.1% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.
Wall Street Analyst Weigh In
MRK has been the subject of a number of recent analyst reports. Truist Financial reaffirmed a "hold" rating and set a $110.00 price target (down from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. Cantor Fitzgerald assumed coverage on Merck & Co., Inc. in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $85.00 target price for the company. Bank of America dropped their price target on shares of Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating on the stock in a research note on Wednesday, February 5th. TD Cowen downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. Finally, BMO Capital Markets dropped their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating on the stock in a research report on Wednesday, February 5th. Twelve equities research analysts have rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $111.13.
View Our Latest Analysis on MRK
About Merck & Co., Inc.
(
Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
